Oablok

Painful overactive bladder. Sudden & frequent urination, & incontinence.

Apply 1 patch once daily to lower abdomen & back, or thigh. Change the skin patch every 24 hr.

History of hypersensitivity. Patients who are unable to urinate; w/ angle-closure glaucoma; severe heart disease; distal stomach obstruction, small intestine/intestinal obstruction; poor stomach or intestinal contractions; muscle weakness (myasthenia gravis). Lactation.

Temporarily discontinue use if skin symptoms continue to appear. Use under high temp conditions. Patients w/ lower urinary tract obstruction (eg, enlarged prostate); dementia or cognitive impairment, or mental abilities that are unable to recognize symptoms of gastritis; hyperthyroidism; heart attack; cardiac arrhythmias; ulcerative colitis; Parkinson's disease or those w/ cerebral artery abnormalities. Take history of the patient & diagnose other diseases eg, UTI, urinary tract stones, cancer, lower urinary tract cancers (eg, bladder & prostate cancer). Measure vol of urine remaining in the bladder in patients w/ lower urinary tract obstruction eg, enlarged prostate. Change the location of use if skin symptoms occur. Caution when operating potentially hazardous machinery due to potential interference w/ eye focus (eg, visual disturbance, blurry vision), dizziness &/or drowsiness. Serious kidney abnormalities & liver disorders. Delayed renal excretion may occur. Avoid use during pregnancy. Not to be used in lactation. Not recommended in patients <20 yr. Elderly (decreased physiological function).

Dry mouth; skin inflammation at application site. Constipation, stomach/upper stomach pain, gastritis, diarrhea, stomatitis, lip inflammation, indigestion; drowsiness, dizziness; difficulty urinating, cystitis, urinary retention in bladder, protein, +ve WBC & RBC in urine; redness, itchiness, rash dermatitis & skin blisters at application site; increased ventricular contraction of the heart; hives, dermatitis; increased AST, ALT, γ-glutamyl transpeptidase, serum bilirubin & urinary urobilinogen; increased eosinophils, WBC monocytes, basophils & platelet count, increased/decreased WBC & neutrophil WBC count, decreased lymphocyte count; malaise, increased/decreased LDH enzyme, increased serum cholesterol.

Enhanced anticholinergic effects w/ drugs w/ anticholinergic effects, TCAs, phenothiazines, MAOIs. Increased serum conc w/ CYP3A4 inhibitors eg, ketoconazole, itraconazole.

Drugs for Bladder & Prostate Disorders

G04BD04 - oxybutynin ; Belongs to the class of urinary antispasmodics.

D